CytomX Therapeutics Announces New Employment Inducement Grant
2020年3月17日 - 5:23AM
CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced that on March 2,
2020, the Company granted two new employees options to purchase a
total of 70,000 shares of the Company’s common stock at an exercise
price per share equal to $3.61, which was the closing trading price
on March 16, 2020, the date of the grant.
The stock options were granted pursuant to the Company’s 2019
Employment Inducement Incentive Plan, which was approved by the
Company’s board of directors in September 2019 under Rule
5635(c)(4) of The Nasdaq Global Market for equity grants to induce
new employees to enter into employment with the Company.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical
company with a vision of transforming lives with safer, more
effective therapies. We are developing a novel class of
investigational antibody therapeutics, based on our Probody®
technology platform, for the treatment of cancer. As leaders in the
field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential best-in-class
immunotherapies against clinically validated targets and potential
first-in-class therapeutics against novel, difficult to drug
targets. Five novel drug-candidates utilizing our Probody
technology are in the clinic, with three in Phase 2 studies and two
in Phase 1 studies. These clinical programs include cancer
immunotherapies against validated targets such as a PD-L1-targeting
Probody therapeutic wholly owned by CytomX (CX-072) and the
CTLA-4-targeting Probody therapeutics partnered with Bristol-Myers
Squibb (BMS-986249 and BMS-986288). The CytomX clinical stage
pipeline also includes first-in-class Probody drug conjugates
against previously undruggable targets, including a CD166-targeting
Probody drug conjugate wholly owned by CytomX (CX-2009) and a
CD71-targeting Probody drug conjugate partnered with AbbVie
(CX-2029). CD166 and CD71 are among cancer targets that are
considered to be inaccessible to conventional antibody drug
conjugates due to their presence on many healthy tissues. In
addition to its wholly owned programs, CytomX has strategic
collaborations with AbbVie, Amgen and Bristol-Myers Squibb. For
additional information about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
PROBODY is a U.S. registered trademark of CytomX Therapeutics,
Inc.
Contact:
Investors and Media:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024